Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
See detailPrévenir les mammites bovines - Techniques et outils en 2012
Theron, Léonard ULg; Hanzen, Christian ULg

Conference given outside the academic context (2012)

Detailed reference viewed: 56 (6 ULg)
Peer Reviewed
See detailPréventeurs de tous les pays, unissez-vous
Lemaître, André ULg

in Revue de Droit Pénal et de Criminologie (1996), 7-8

Detailed reference viewed: 4 (2 ULg)
Full Text
Peer Reviewed
See detailPreventie van postmenopauzale osteoporose
Reginster, Jean-Yves ULg; Halkin, V

in De agenda Gynaecologie (2000), 19

Detailed reference viewed: 2 (1 ULg)
Full Text
See detailPreventing Violence in sport: A guidebook for cities
Comeron, Manuel ULg; Bures, Radim; Johnston, Elizabeth

Report (2012)

Large sports events, in football in particular, have become global and attract increasingly large audiences on site and through media and broadcasting. Their impact on public life is growing accordingly ... [more ▼]

Large sports events, in football in particular, have become global and attract increasingly large audiences on site and through media and broadcasting. Their impact on public life is growing accordingly, above all in host cities, since they are on the front line when it comes to ensure safety and security in and around stadiums, for spectators and local inhabitants. The objective of this publication is to support cities in the prevention of sport-related violence through the promotion of a multisectoral and comprehensive approach. [less ▲]

Detailed reference viewed: 72 (10 ULg)
Full Text
Peer Reviewed
See detailPreventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?
Scheen, André ULg

in Diabetes Care (2003), 26(9), 27012701-3

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailPrévention - normes de construction - Introduction à l'Eurocode 8 et à son annexe nationale belge
Plumier, André ULg; Degée, Hervé ULg

in Actes du Colloque "Evaluation et prévention du risque sismique en Région Wallonne" (2006)

Detailed reference viewed: 194 (4 ULg)
Full Text
See detailPrevention and management of violence in Belgian psychiatric institutions: do current practices respect international guidelines?
Lardenois, Miguel; Duquesne, Patricia; Gillain, Nicolas ULg et al

Poster (2007, October)

Detailed reference viewed: 26 (7 ULg)
See detailPrevention and Mitigation of Societal Disruption
Brunet, Sébastien ULg

Report (2003)

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention and treatment of major blood loss
Detry, Olivier ULg; De Roover, Arnaud ULg; Honore, Pierre ULg

in New England Journal of Medicine [=NEJM] (2007), 357(12), 1261-1261

Detailed reference viewed: 53 (14 ULg)
See detailPrevention and treatment of postmenopausal osteoporosis.
Neuprez, Audrey ULg; Reginster, Jean-Yves ULg

in Rizzoli, R. (Ed.) Atlas of postmenopausal osteoporosis (2010)

Detailed reference viewed: 26 (6 ULg)
Full Text
Peer Reviewed
See detailPrevention and treatment of postmenopausal osteoporosis. National consensus of the Belgian Bone Club"
Kaufman, JM; Devogelaer, JP; Raeman, F et al

in Clinical Rheumatology (1997), 16(4), 343-345

Detailed reference viewed: 12 (4 ULg)
Full Text
Peer Reviewed
See detailPrevention cardio-vasculaire chez le patient diabetique de type 2.
Paquot, Nicolas ULg; Scheen, André ULg

in Revue Médicale de Liège (2003), 58(5), 271-4

It is estimated that 80% of individuals with type 2 diabetes die of cardiovascular diseases. Several factors account for the accelerated atherosclerosis present in diabetic patients. These include ... [more ▼]

It is estimated that 80% of individuals with type 2 diabetes die of cardiovascular diseases. Several factors account for the accelerated atherosclerosis present in diabetic patients. These include hyperglycaemia, dyslipidaemia, hypertension and prothrombotic state. Hypoglycaemic agents, statin or fibrates that improve dyslipidaemia, anti-hypertensive agents, aspirin and healthy lifestyle can modify these factors and have been shown to reduce morbidity and mortality caused by coronary heart disease in diabetic patients. It was recently demonstrated that a multifactorial intervention on modifiable risk factors of cardiovascular disease in type 2 diabetic patients dramatically reduces the incidence of cardiovascular events. Thus, an intensified intervention aimed at multiple risk factors should be recommended in patients with type 2 diabetes. [less ▲]

Detailed reference viewed: 697 (4 ULg)
Full Text
Peer Reviewed
See detailPrevention cardio-vasculaire par les statines: faut-il encore doser le cholesterol?
Scheen, André ULg; Kulbertus, Henri ULg

in Revue Médicale de Liège (2003), 58(4), 191-7

Statins, the most popular lipid-lowering agents, have proven their efficacy in preventing cardiovascular events in subjects with lower and lower initial plasma cholesterol levels. Besides, the protective ... [more ▼]

Statins, the most popular lipid-lowering agents, have proven their efficacy in preventing cardiovascular events in subjects with lower and lower initial plasma cholesterol levels. Besides, the protective effect does not seem to be directly related neither to the degree of the cholesterol reduction nor to the final level of plasma cholesterol level reached under treatment. Such observations suggest that statins may exert vascular protective effects, at least in part, independently of their specific cholesterol-lowering effect (so-called pleiotropic effects). The present paper will discuss the arguments pro and contra the dosage of cholesterolaemia before initiating a therapy with statin and during treatment follow up, both in subjects with previous cardiovascular events (secondary prevention) and in subjects with a high cardiovascular absolute risk but without previous clinical expression of atherosclerosis (primary prevention). [less ▲]

Detailed reference viewed: 402 (0 ULg)
Full Text
See detailPrévention cardio-vasculaire. La pratique des médecins généralistes de la région liégeoise
Ketterer, Frédéric ULg; Duchesnes, Christiane ULg; MASSART, Valérie ULg et al

Report (2011)

Ce rapport s'intègre dans une étude plus générale intitulée NESCAV (Nutrition, Environnement, santé cardio-vasculaire), financée par la Commission européenne. L'étude présentée ici visait à avoir un ... [more ▼]

Ce rapport s'intègre dans une étude plus générale intitulée NESCAV (Nutrition, Environnement, santé cardio-vasculaire), financée par la Commission européenne. L'étude présentée ici visait à avoir un aperçu des actions de prévention cardio-vasculaire menées par les médecins généralistes auprès de leurs patients, dans la région liégeoise. L'étude est composée de quatre focus groups, soit un total de 39 médecins généralistes interrogés. [less ▲]

Detailed reference viewed: 18 (9 ULg)
Full Text
Peer Reviewed
See detailPrevention cardio-vasculaire: la "polypill", une solution pour vaincre l'inertie clinique et le manque d'observance?
Scheen, André ULg; Lefebvre, Pierre ULg; Kulbertus, Henri ULg

in Revue Médicale de Liège (2010), 65(5-6), 267-72

The concept of "polypill" for cardiovascular prevention was introduced in 2003 in a landmark paper of the British Medical Journal. A model based on results provided by evidence-based medicine suggested ... [more ▼]

The concept of "polypill" for cardiovascular prevention was introduced in 2003 in a landmark paper of the British Medical Journal. A model based on results provided by evidence-based medicine suggested that a "polypill", that contains a statin, three blood pressure lowering drugs (each at half standard dose), aspirin and folic acid, would result in an 80% reduction in the incidence of coronary and cerebrovascular events, while being associated with a good tolerance profile and offering a favourable cost-effectiveness ratio. The present paper aims at presenting the new advances dealing with this new paradigm in cardiovascular prevention. We will present the progresses of the "polypill" concept since 2003, the results of a first controlled clinical trial, the pharmaceutical feasibility for routine clinical use and the potential pharmaco-economical impacts of such a strategy. The "polypill" may offer a solution to avoid physician's clinical inertia and reduce patients's lack of compliance, two drawbacks in the field of cardiovascular prevention. [less ▲]

Detailed reference viewed: 83 (0 ULg)
Full Text
Peer Reviewed
See detailPrevention cardiovasculaire chez la personne agee
Lebois, Florence ULg; Allepaerts, Sophie ULg; Lancellotti, Patrizio ULg et al

in Revue Médicale de Liège (2003), 58(5), 275-8

The aging of the cardiovascular system leads to an increased incidence of hypertension, coronary artery disease and ischemic stroke. Since cardiovascular disease is the leading cause of morbidity and ... [more ▼]

The aging of the cardiovascular system leads to an increased incidence of hypertension, coronary artery disease and ischemic stroke. Since cardiovascular disease is the leading cause of morbidity and mortality in patients > or = 70 years old, prevention seems crucial for improving quality of life and reducing medical costs. In this article we present some aspects of cardiovascular prevention in elderly patients. [less ▲]

Detailed reference viewed: 12 (3 ULg)
Full Text
Peer Reviewed
See detailPrevention cardiovasculaire par l'aspirine chez le patient diabetique: que nous apprend la medecine factuelle?
Legrand, Delphine ULg; Scheen, André ULg

in Revue Médicale Suisse (2006), 2(76), 1904-8

Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. Aspirin prescription is mandatory in secondary prevention, even if the ... [more ▼]

Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. Aspirin prescription is mandatory in secondary prevention, even if the protection by aspirin appears less efficacious in diabetic than in non-diabetic patients. In primary prevention, available data are paradoxically rather scarce, but also suggest a less effective prevention when diabetes is present. Aspirin remains the first antiplatelet agent in the diabetic population in all international guidelines of cardiovascular prevention although a higher daily dose may be proposed in this subgroup of patients (160-300 mg rather than 75-100 mg). [less ▲]

Detailed reference viewed: 75 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention de l'apparition du diabete de type 2 par l'inhibition du systeme renine-angiotensine.
Scheen, André ULg

in Revue Médicale de Liège (2002), 57(7), 449-52

Type 2 diabetes mellitus and arterial hypertension are part of the insulin resistance syndrome. Besides a metabolic component, insulin resistance has also an haemodynamic component, especially in relation ... [more ▼]

Type 2 diabetes mellitus and arterial hypertension are part of the insulin resistance syndrome. Besides a metabolic component, insulin resistance has also an haemodynamic component, especially in relation with an endothelial dysfunction. Some studies suggested that inhibitors of angiotensin converting enzyme can improve insulin sensitivity. Interestingly enough, three clinical trials recently reported concordant results showing that the inhibition of the renin-angiotensin system significantly reduces the risk of developing type 2 diabetes in patients at high risk of vascular complications, essentially with hypertension: the CAPPP trial with captopril (-14%, p = 0.39), the HOPE study with ramipril (-34%, p < 0.001) and the LIFE study with losartan (-25%, p < 0.001). However, these observations could be criticized because such a protective effect was only considered as a secondary endpoint in these studies. Two large prospective, controlled, randomized, double-blind trials are ongoing to specifically confirm this interesting hypothesis, one with ramipril and the other with valsartan. [less ▲]

Detailed reference viewed: 105 (0 ULg)